The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 0.00 (0.00%)
Spread: 0.50 (0.029%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 3-Zika virus set to spread across Americas, spurring vaccine hunt

Mon, 25th Jan 2016 17:14

* Mosquito-borne virus linked to birth defects in Brazil

* Brazil's Butantan Institute aims to develop vaccine

* GSK and Sanofi reviewing vaccine possibilities

* More research needed into potential sexual transmission (Adds comment from GlaxoSmithKline and Sanofi, graphic link)

By Tom Miles and Ben Hirschler

GENEVA/LONDON, Jan 25 (Reuters) - The mosquito-borne Zikavirus, which has been linked to brain damage in thousands ofbabies in Brazil, is likely to spread to all countries in theAmericas except for Canada and Chile, the World HealthOrganization said on Monday.

Zika transmission has not yet been reported in thecontinental United States, although a woman who fell ill withthe virus in Brazil later gave birth to a brain-damaged baby inHawaii.

Brazil's Health Ministry said in November that Zika waslinked to a foetal deformation known as microcephaly, in whichinfants are born with smaller-than-usual brains.

Brazil has reported 3,893 suspected cases of microcephaly,the WHO said last Friday, over 30 times more than in any yearsince 2010 and equivalent to 1-2 percent of all newborns in thestate of Pernambuco, one of the worst-hit areas.

The Zika outbreak comes hard on the heels of the Ebolaepidemic in West Africa, demonstrating once again howlittle-understood diseases can rapidly emerge as global threats.

"We've got no drugs and we've got no vaccines. It's a caseof deja vu because that's exactly what we were saying withEbola," said Trudie Lang, a professor of global health at theUniversity of Oxford. "It's really important to develop avaccine as quickly as possible."

Large drugmakers' investment in tropical disease vaccineswith uncertain commercial prospects has so far been patchy,prompting health experts to call for a new system of incentivesfollowing the Ebola experience.

"We need to have some kind of a plan that makes (companies)feel there is a sustainable solution and not just a one-shotdeal over and over again," Francis Collins, director of the U.S.National Institutes of Health, said last week.

The Sao Paulo-based Butantan Institute is currently leadingthe research charge on Zika and said last week it planned todevelop a vaccine "in record time", although its director warnedthis was still likely to take three to five years.

British drugmaker GlaxoSmithKline said on Monday itwas studying the feasibility of using its vaccine technology onZika, while France's Sanofi said it was reviewingpossibilities.

RIO CONCERNS

The virus was first found in a monkey in the Zika forestnear Lake Victoria, Uganda, in 1947, and has historicallyoccurred in parts of Africa, Southeast Asia and the PacificIslands. But there is little scientific data on it and it isunclear why it might be causing microcephaly in Brazil.

Laura Rodrigues of the London School of Hygiene and TropicalMedicine said it was possible the disease could be evolving.

If the epidemic was still going on in August, when Brazil isdue to host the Olympic Games in Rio de Janeiro, then pregnantwomen should either stay away or be obsessive about covering upagainst mosquito bites, she said.

The WHO advised pregnant women planning to travel to areaswhere Zika is circulating to consult a healthcare providerbefore travelling and on return.

The clinical symptoms of Zika are usually mild and oftensimilar to dengue, a fever which is transmitted by the sameAedes aegypti mosquito, leading to fears that Zika will spreadinto all parts of the world where dengue is commonplace.

More than one-third of the world's population lives in areasat risk of dengue infection, in a band stretching throughAfrica, India, Southeast Asia and Latin America.

Zika's rapid spread, to 21 countries and territories in theAmericas since May 2015, is due to the prevalence of Aedesaegypti and a lack of immunity among the population, the WHOsaid in a statement.

RISK TO GIRLS

Like rubella, which also causes mild symptoms but can leadto birth defects, health experts believe a vaccine is needed toprotect girls before they reach child-bearing age.

Evidence about other transmission routes, apart frommosquito bites, is limited.

"Zika has been isolated in human semen, and one case ofpossible person-to-person sexual transmission has beendescribed. However, more evidence is needed to confirm whethersexual contact is a means of Zika transmission," the WHO said.

While a causal link between Zika and microcephaly has notyet been definitively proven, WHO Director-General Margaret Chansaid the circumstantial evidence was "suggestive and extremelyworrisome".

In addition to finding a vaccine and potential drugs tofight Zika, some scientists are also planning to take the fightto the mosquitoes that carry the disease.

Oxitec, the UK subsidiary of U.S. synthetic biology companyIntrexon, hopes to deploy a self-limiting geneticallymodified strain of insects to compete with normal Aedes aegypti.

Oxitec says its proprietary OX513A mosquito succeeded inreducing wild larvae of the Aedes mosquito by 82 percent in anarea of Brazil where 25 million of the transgenic insects werereleased between April and November. Authorities reported a bigdrop in dengue cases in the area.

(Editing by Mark Trevelyan)

More News
31 Jan 2024 08:55

LONDON MARKET OPEN: Stocks lack direction ahead of Fed, BoE

(Alliance News) - Stock prices in London lacked direction at the open on Wednesday, as investors nervously look ahead to interest rate decisions from the US Federal Reserve and Bank of England.

Read more
31 Jan 2024 07:46

LONDON BRIEFING: Stocks called up; GSK revenue and profit up

(Alliance News) - Stocks in London are called to open higher, as markets share of nerves around the next set of interest rate decisions.

Read more
29 Jan 2024 08:51

GSK seeks expanded use of RSV vaccine in EU, wins approval for Omjjara

(Alliance News) - GSK PLC on Monday celebrated regulatory progress for two of its products in the EU.

Read more
29 Jan 2024 07:43

LONDON BRIEFING: Superdry looks at saving costs; Ferrexpo loses case

(Alliance News) - Stocks in London are expected to start the week on a cautious note, as investors nervously look ahead to two key interest rate decisions.

Read more
29 Jan 2024 07:07

GSK gets EU approval to sell blood cancer treatment Omijara

(Sharecast News) - Biopharma giant GSK has been given the green light by European regulators to sell Omjjara, its treatment for patients with a rare type of blood cancer.

Read more
26 Jan 2024 10:47

Citi hikes target price for GSK but stays 'neutral'

(Sharecast News) - Shares in biopharma giant GSK were rising on Friday, helped by forecast upgrades from Citi, which raised its target price on the stock from 1,535p to 1,700p.

Read more
24 Jan 2024 15:08

Private equity firm Yellow Wood close to deal to acquire ChapStick-sources

Jan 24 (Reuters) - Private equity firm Yellow Wood Partners is in advanced talks to acquire ChapStick, a lip balm brand, from Haleon Plc, the former consumer health division of drug developer GSK Plc, four people familiar with the matter said.

Read more
24 Jan 2024 14:34

UK earnings, trading statements calendar - next 7 days

Thursday 25 January 
Britvic PLCTrading Statement
Conduit Holdings LtdTrading Statement
CVS Group PLCTrading Statement
Dr Martens PLCTrading Statement
Fevertree Drinks PLCTrading Statement
Foxtons Group PLCFull Year Results
Fuller, Smith & Turner PLCTrading Statement
Halfords Group PLCTrading Statement
Idox PLCFull Year Results
IG Group Holdings PLCHalf Year Results
Intermediate Capital Group PLCTrading Statement
Mitie Group PLCTrading Statement
NCC Group PLCHalf Year Results
Newmark Security PLCHalf Year Results
Next 15 Group PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Secure Trust Bank PLCTrading Statement
St James's Place PLCTrading Statement
Time Finance PLCHalf Year Results
Titon Holdings PLCFull Year Results
Wizz Air Holdings PLCQ3 Results
Workspace Group PLCTrading Statement
Friday 26 January 
Paragon Banking Group PLCTrading Statement
Record PLCTrading Statement
Superdry PLCHalf Year Results
Taylor Maritime Investments LtdTrading Statement
WH Smith PLCTrading Statement
YouGov PLCTrading Statement
Monday 29 January 
Team Internet Group PLCTrading Statement
Tuesday 30 January 
Diaceutics PLCTrading Statement
Diageo PLCHalf Year Results
Kromek Group PLCHalf Year Results
Luceco PLCTrading Statement
Oxford Cannabinoid Technologies Holdings PLCHalf Year Results
Pets at Home Group PLCTrading Statement
Renewi PLCTrading Statement
Saga PLCTrading Statement
SSP Group PLCTrading Statement
SThree PLCFull Year Results
Synthomer PLCTrading Statement
Wednesday 31 January 
Aberforth Smaller Companies Trust PLCFull Year Results
abrdn Private Equity Opportunities Trust PLCFull Year Results
Ecora Resources PLCTrading Statement
GSK PLCFull Year Results
ITM Power PLCHalf Year Results
NWF Group PLCHalf Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
22 Jan 2024 21:22

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies are urging a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 17:08

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies will urge a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 09:34

IN BRIEF: Oxford Nanopore appoints Keher to CFO as Cowper becomes COO

Oxford Nanopore Technologies - Oxford, England-based company specialising in nanopore DNA-sequencing - Appoints Nick Keher as chief financial officer and director, effective immediately. Keher will replace Tim Cowper as he moves into a new role as Oxford Nanopore's chief operating officer. The company says that Cowper has been performing the majority of COO duties for the past five years, and that he will lead the company's efforts to expand its international footprint. The company also says that new CFO Keher possesses "significant experience of financial leadership of complex, scientific businesses", having served in similar roles at Clinigen Group PLC, BenevolentAI SA, Royal Bank of Canada, Investec PLC and GSK PLC.

Read more
17 Jan 2024 09:38

UPDATE: GSK raises GBP978 million as cuts stake in Haleon to 4.2%

(Alliance News) - GSK PLC early Wednesday confirmed it agreed to sell 300 million shares in Haleon PLC, reducing its remaining stake in the consumer healthcare products spin-off to just 4.2%.

Read more
17 Jan 2024 08:05

GSK raises £978m through Haleon share sale

(Sharecast News) - GSK said on Wednesday that it has raised around £978m from the sale of shares in Haleon.

Read more
17 Jan 2024 07:46

LONDON BRIEFING: UK inflation surprises as unexpectedly rises to 4.0%

(Alliance News) - Stocks in London are called to open lower on Wednesday, following some hotter-than-expected consumer price data from the UK.

Read more
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.